Activity Summary:
Build a practical foundation for recognizing and managing NF1-PN. These evidence-based mini-modules explores the biology and clinical presentation of NF1-PN, with a focus on early recognition, clinical decision-making, and appropriate next steps in care.

Continue exploring a collection of downloadable resources designed to support learning and clinical application from our recent activity, From Recognition to Lifelong Management in NF1-PN

Available Resources:

Downloadable Slides
Review presentation slides with key data, visuals, and clinical insights.

Reference and Resource
Access to featured studies, abstracts, and other kit materials cited in the program.

Podcast Transcript
Download the transcript for convenient text-based review anytime.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Build a practical foundation for recognizing and managing NF1-PN. These evidence-based mini-modules explores the biology and clinical presentation of NF1-PN, with a focus on early recognition, clinical decision-making, and appropriate next steps in care.

Explore the fundamentals of recognizing and managing NF1-PN through these engaging, evidence-based podcasts. Hear expert insights on disease biology, clinical presentation, early recognition, and decision-making, including the rationale for MEK pathway targeting and key features that may warrant further evaluation or referral.

Designed for front-line clinicians, these podcasts provide practical perspectives to build confidence in recognizing NF1-PN, understanding emerging treatment approaches, and navigating early management decisions in a rapidly evolving therapeutic landscape.

Activity Summary:
Build a practical foundation for recognizing and managing NF1-PN. These evidence-based mini-modules explores the biology and clinical presentation of NF1-PN, with a focus on early recognition, clinical decision-making, and appropriate next steps in care.

Through clinical case scenarios and practical learning activities, participants will strengthen their understanding of NF1-PN pathophysiology, the rationale for MEK pathway targeting, and the clinical features that should prompt further evaluation or referral.

Designed for front-line clinicians, these foundational modules provide the knowledge and confidence to recognize NF1-PN, understand emerging treatment approaches, and navigate early management decisions in a rapidly evolving therapeutic landscape.

Activity Summary:
To further build on the insights presented in the Clinical Clips® in NF1-PN: Key Advances from AAN 2026 by Dr. Angela Hirbe, HCPs can access a range of downloadable resources designed to reinforce key concepts and support practical application in clinical care.

Available Resources:

Clinical Snippet Highlights: AAN 2026 Evidence at a Glance
A PDF summarizing each key presentation or poster featured in the Clinical Clip, with evidence-based takeaways for each study.

Downloadable Slide Deck (PDF)
Downloadable version of the presentation slides used by the faculty, including data visuals, figures, and key discussion points.

Expert Commentary Transcript
A transcript of the podcast version of the program, reflecting the expert discussion and interpretation of AAN 2026 data.

Discussion Guide: Applying Emerging NF1 Evidence Across the Lifespan
A brief guide with reflective questions and prompts related to patient selection, interpretation of outcomes beyond imaging, and longitudinal management considerations.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
To further expand knowledge from the Advancing Myasthenia Gravis Care: Emerging Insights from AAN 2026 presented by Dr. James Howard Jr., HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights: AAN 2026 Evidence in Myasthenia Gravis
A summary highlighting each abstract, presentation, or poster discussed in the Clip, with key findings, clinical relevance, and practical takeaways.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Podcast Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

Diagnostic and Severity Assessment Quick Reference
A reference guide summarizing diagnostic considerations, testing options, and commonly used severity assessment tools discussed in the program.

Emerging Treatment Landscape Overview
An overview outlining emerging treatment strategies covered in the Clip, including mechanisms of action and potential clinical considerations.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides a synthesis of key findings, highlight their relevance across pediatric and adult care, and frames practical considerations for patient assessment and longitudinal management.

Activity Summary:
Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Activity Summary:
Neurofibromatosis type 1 (NF1) treatment is evolving rapidly, with new data emerging across clinical trials and real-world studies. For busy clinicians, the challenge is not access to information, but quickly understanding what is clinically meaningful and how it should influence care.

This Clinical Clip from AAN 2026 delivers a focused, expert-led review of emerging NF1-PN treatment data in just 10-minutes. Designed for real-world practice, this concise update highlights key findings, clarifies their clinical relevance, and provides practical insights to support patient selection and treatment decisions.

Watch the clip to stay current, sharpen your clinical thinking, and translate new evidence into action.

Activity Summary:
Myasthenia gravis care is advancing quickly, with new evidence shaping how clinicians approach disease assessment and treatment selection. At the same time, variability in presentation, delays in diagnosis, and uncertainty around integrating emerging therapies continue to create challenges in clinical practice. Clinicians need concise, practical education that translates evolving data into clear and actionable strategies that can be applied in real-world care.

This focused Clinical Clip from AAN 2026 features Dr James (Chip) Howard, a leading expert in myasthenia gravis, delivering a 20-minute update on the most clinically relevant advances presented in Chicago. Designed for efficiency and practical application, this program highlights how to incorporate emerging therapies into individualized treatment plans to support confident, evidence-based decision-making.

Activity Summary:

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Activity Summary:

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:
Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Drs C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this Clinical Clip activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
Stroke prevention continues to challenge clinicians, especially when balancing effective anticoagulation with the risks of bleeding. During this video series, Drs C. Michael Gibson and Manesh Patel provide rapid updates on the latest science shaping stroke prevention. Each 10–15-minute episode delivers digestible insights on topics such as emerging anticoagulation strategies, residual stroke risk, and clinical trial takeaways. This series is perfect for time-pressed healthcare professionals as it offers actionable knowledge designed to support evidence-based decision-making.

Activity Summary:
Myasthenia Gravis (MG) has had significant advances, however critical gaps persist in optimizing care. Challenges include variability in diagnostic accuracy, particularly in seronegative cases, and a limited adoption of newer, more sensitive testing modalities. Additionally, the evolving treatment landscape—with emerging therapies such as complement inhibitors and FcRn antagonists—highlights the need for clinicians to stay informed about the latest evidence and integrate these options into personalized care strategies. Addressing these gaps is crucial to improving patient care, enhancing quality of life, and reducing the burden of long-term side effects associated with traditional treatments.

This special edition podcast series with Dr. Nicholas Silvestri enables healthcare providers to engage with evidence-based insights and practical guidance on MG management at their convenience. The podcast format is ideal for professionals to access while commuting, during breaks, or between patient appointments, providing targeted learning without disrupting their workflow.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025.

Activity Summary:
In this Clinical Clip, Dr. Nicholas Silvestri provides a concise and clinically relevant summary of the most important emerging data presented at AAN 2025 that impact the management of generalized Myasthenia Gravis (gMG).

Topics covered include pivotal updates from recent clinical trials—such as MINT (inebilizumab), ADAPT NXT (efgartigimod), and MycarinG (rozanolixizumab)—highlighting the safety, efficacy, and practical implications of emerging therapies across diverse MG subtypes. The activity also explores trends in real-world treatment patterns, therapeutic inertia among neurologists, and new diagnostic approaches including advanced serologic testing and AI-supported electrophysiologic tools. With a focus on individualized care, this activity equips healthcare professionals with key insights to help integrate new therapies and diagnostic innovations into practice, ultimately supporting timely, targeted, and patient-centered management of MG.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. 

In this video presentation, Dr Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:

Drs. Smith and Pellock will provide an expert analysis of the identification of Lennox-Gastaut syndrome in adults, optimal treatment options, and transition of care. The transition of pediatric patients to adults remains a challenge for providers and requires a global multidisciplinary approach.

Activity Summary:
Dr. Smith and Dr. DeToledo provide an expert review of refractory epilepsy, including proper diagnosis, imaging, seizure types, and treatment options including AEDs, surgery, VNS, and dietary considerations.